# OnCo record nct06801834 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06801834/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06801834", "NCT06801834" ;
  schema:name "Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer"@en ;
  schema:alternateName "EVOKE-SCLC-04"@en ;
  schema:description "A phase 3 trial of Sacituzumab govitecan, Topotecan, Amrubicin in small-cell lung cancer, run by Gilead Sciences, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06801834/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06801834> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-04-04" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/amrubicin/>, <https://onco.cc/drugs/lurbinectedin/> ;
  onco:companies <https://onco.cc/companies/gilead/> .